NDSI
RGNX icon

Newman Dignan & Sheerar Inc’s Regenxbio RGNX Stock Holding History

Newman Dignan & Sheerar Inc’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,522
Closed -$205 – 186
2020
Q4 		$205 Buy
+4,522
New +$158K 0.03% 167

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Newman Dignan & Sheerar Inc's RGNX Position: Q1 2021 in Review

Newman Dignan & Sheerar Inc sold out of Regenxbio (RGNX) in Q1 2021, closing a stake of 4,522 shares — an estimated $205 sold.

Newman Dignan & Sheerar Inc first reported a position in RGNX in Q4 2020 and held it in 1 quarter. The position peaked at $205 in Q4 2020. 184 funds tracked by Wall St. Rank hold RGNX as of Q1 2021.

  • Newman Dignan & Sheerar Inc reported no remaining Regenxbio position as of Q1 2021 after selling out during the quarter.
  • Newman Dignan & Sheerar Inc sold 4,522 Regenxbio shares in Q1 2021, an estimated $205.
  • Newman Dignan & Sheerar Inc first reported a position in Regenxbio in Q4 2020 and held it in 1 quarter.
  • Newman Dignan & Sheerar Inc's Regenxbio position peaked at $205 in Q4 2020.
  • 184 funds tracked by Wall St. Rank held Regenxbio as of Q1 2021.

Based on Newman Dignan & Sheerar Inc's 13F filing for Q1 2021, filed 5 May 2021.